CXCL16 Antibody [Unconjugated]

Raw 264.7 cells were stained with Goat Anti-Mouse CXCL16 Antigen Affinity-purified Polyclonal Antibody (Catalog # af503, filled histogram) or isotype control antibody (Catalog # AB-108-C, open histogram) followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0108). View our protocol for Staining Membrane-associated Proteins.

Recombinant Mouse CXCL16 Chemokine Domain (Catalog # 503-CX) chemoattracts the BaF3 mouse pro‑B cell line transfected with mouse CXCR6 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse CXCL16 Chemokine Domain (7.5 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse CXCL16 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF503). The ND50 is typically 0.1-0.4 µg/mL.

• Reactivity: Mu
• Applications: WB, Flow, B/N, CyTOF-ready
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

CXCL16 Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant mouse CXCL16
  Asn27-Pro114
  Accession # Q8BSU2
• Specificity: Detects mouse CXCL16 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human (rh) CXCL16, rhFractalkine, recombinant mouse Fractalkine, and recombinant rat Fractalkine is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CXCL16
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells
  • Neutralization 0.1-0.4 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
  *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL16 Antibody [Unconjugated]

• chemokine (C-X-C motif) ligand 16
• CXC chemokine ligand 16
• CXCL16
• CXCLG16
• Scavenger receptor for phosphatidylserine and oxidized low density lipoprotein
• SCYB16
• Small-inducible cytokine B16
• SRPSOXC-X-C motif chemokine 16
• SR-PSOXTransmembrane chemokine CXCL16

Background

Mouse CXCL16 (CXC chemokine 16) is a non-ELR motif-containing CXC chemokine with a transmembrane domain. CX3CL1/Fractalkine and CXCL16 are the only two transmembrane chemokines within the superfamily. Mouse CXCL16 cDNA encodes a 246 amino acid (aa) precursor protein with a putative 26 aa residue signal peptide, an 88 aa residue chemokine domain, an 87 aa residue mucin-like spacer region, a 22 aa residue transmembrane domain, and a 23 aa residue cytoplasmic tail. Mouse and human CXCL16 share 49% overall aa identity and 70% similarity in the chemokine domains. Mouse CXCL16 is produced by dendritic cells in lymphoid organ T cell zones and by cells in the splenic red pulp both as membrane-bound and soluble forms. Based on northern blot analysis, CXCL16 is also expressed in some nonlymphoid tissues such as lung, small intestine and kidney. The receptor for CXCL16 has been identified as CXCR6/Bonzo (STRL33 and TYMSTR), a receptor previously shown to be a co-receptor for HIV entry. CXCR6 is expressed on naive CD8 cells, natural killer T cells and activated CD8 and CD4 T cells.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CXCL16 Antibody (AF503)(16)

Publications using AF503

• Leroux, L-P;Chaparro, V;Plouffe, A;Johnston, B;Jaramillo, M; Toxoplasma gondii infection induces the expression of the chemokine CXCL16 in macrophages to promote chemoattraction of CXCR6+ cells Infection and immunity 2024-10-22 [PMID: 39436058] (Flow Cytometry, Western Blot, Neutralization, Mouse)
• Wu, J;Wang, W;Yuan, F;Zheng, J;Zhang, W;Guo, H;Wang, L;Dai, C;Han, F;Wu, X;Gao, J; CXCL16 exacerbates Pseudomonas aeruginosa keratitis by promoting neutrophil activation International immunopharmacology 2023-12-27 [PMID: 38154213] (In vivo assay, Mouse)
• A Vorontsova, TJ Cooper, J Haj-Shomal, M Benguigui, S Levin, B Manobla, R Menachem, M Timaner, Z Raviv, Y Shaked Chemotherapy-induced tumor immunogenicity is mediated in part by megakaryocyte-erythroid progenitors Oncogene, 2023-01-16;0(0):. 2023-01-16 [PMID: 36646904] (Neutralization, Mouse)
• F Mirshahi, HF Aqbi, M Isbell, SH Manjili, C Guo, M Saneshaw, M Dozmorov, A Khosla, K Wack, OM Carrasco-Z, MO Idowu, XY Wang, AJ Sanyal, MH Manjili, D Bandyopadh Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma Cell Reports, 2022-03-01;38(9):110454. 2022-03-01 [PMID: 35235789] (IHC, Mouse)
• Binglin Wang, Yi Wang, Xiaofan Sun, Guoliang Deng, Wei Huang, Xingxin Wu et al. CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell Journal for ImmunoTherapy of Cancer 8/29/2021 [PMID: 34462326]
• Binglin Wang, Yi Wang, Xiaofan Sun, Guoliang Deng, Wei Huang, Xingxin Wu et al. CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell Journal for ImmunoTherapy of Cancer 2021-08-29 [PMID: 34462326] (Immunohistochemistry, Western Blot, Xenograft)
• Saeed S. Akhand, Zian Liu, Stephen C. Purdy, Ammara Abdullah, Hang Lin, Gregory M. Cresswell et al. Pharmacological inhibition of FGFR modulates the metastatic immune microenvironment and promotes response to immune checkpoint blockade Cancer Immunology Research 12/1/2020 [PMID: 33093218]
• V Chaparro, LP Leroux, A Zimmermann, A Jardim, B Johnston, A Descoteaux, M Jaramillo Leishmania donovani lipophosphoglycan increases macrophage-dependent chemotaxis of CXCR6-expressing cells via CXCL16 induction Infect. Immun., 2019-04-23;0(0):. 4/23/2019 [PMID: 30804103]
• SR Zhang, M Piepke, HX Chu, BR Broughton, R Shim, CH Wong, S Lee, MA Evans, A Vinh, S Sakkal, TV Arumugam, T Magnus, S Huber, M Gelderblom, GR Drummond, CG Sobey, HA Kim IL-33 modulates inflammatory brain injury but exacerbates systemic immunosuppression following ischemic stroke JCI Insight, 2018-09-20;3(18):. 2018-09-20 [PMID: 30232272] (IHC, Mouse)
• Maria Rosito, Clotilde Lauro, Giuseppina Chece, Alessandra Porzia, Lucia Monaco, Fabrizio Mainiero et al. Trasmembrane chemokines CX3CL1 and CXCL16 drive interplay between neurons, microglia and astrocytes to counteract pMCAO and excitotoxic neuronal death Frontiers in Cellular Neuroscience 7/10/2014 [PMID: 25071451]
• Maria Rosito, Cristina Deflorio, Cristina Limatola, Flavia Trettel CXCL16 orchestrates adenosine A3 receptor and MCP-1/CCL2 activity to protect neurons from excitotoxic cell death in the CNS The Journal of Neuroscience 2/29/2012 [PMID: 22378888]
• Eberlein J, Nguyen TT, Victorino F, Golden-Mason L, Rosen HR, Homann D Comprehensive assessment of chemokine expression profiles by flow cytometry. J. Clin. Invest., 2010-02-08;120(3):907-23. 2010-02-08 [PMID: 20197626] (Flow Cytometry, Mouse)
• Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, Mackay M, Aranow C, Putterman C, Mohan C Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J. Immunol., 2007-11-15;179(10):7166-75. 2007-11-15 [PMID: 17982109] (IHC, Mouse)
• Wu T, Xie C, Bhaskarabhatla M, Yan M, Leone A, Chen SS, Zhou XJ, Putterman C, Mohan C Excreted urinary mediators in an animal model of experimental immune nephritis with potential pathogenic significance. Arthritis Rheum., 2007-03-01;56(3):949-59. 2007-03-01 [PMID: 17328072] (IHC, Mouse)
• Ueha S, Murai M, Yoneyama H, Kitabatake M, Imai T, Shimaoka T, Yonehara S, Ishikawa S, Matsushima K Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects. J. Leukoc. Biol., 2006-10-19;81(1):176-85. 2006-10-19 [PMID: 17053165] (IHC, Mouse)
• Haas CS, Amin MA, Allen BB, Ruth JH, Haines GK, Woods JM, Koch AE Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum., 2006-08-01;54(8):2402-14. 2006-08-01 [PMID: 16869003] (Neutralization, Rat)

Bioinformatics

• Gene Symbol: CXCL16
• Uniprot:
  • Q8BSU2()